Results 91 to 100 of about 1,976,953 (299)

Advanced Technologies for Oral Controlled Release: Cyclodextrins for oral controlled release [PDF]

, 2011
Cyclodextrins (CDs) are used in oral pharmaceutical formulations, by means of inclusion complexes formation, with the following advantages for the drugs: (1) solubility, dissolution rate, stability and bioavailability enhancement; (2) to modify the drug ...
A Al-Omar, A Latrofa, A Miro, A Trapani, A Vyas, AC Jain, AK Upadhyay, AL Nielsen, AS Hoffman, B Haeberlin, B Pose-Vilarnovo, BN Naidu, C Cannavà, C Rodriguez-Tenreiro, C Rupp, C-Y Chen, Catarina Carvalho, Claúdia Conduto, CM Buchanan, CM Fernandes, D Duchêne, D Duchêne, EA Zannou, EY Kim, F Frézard, F Hirayama, G Corti, G Gladys, G Pescitelli, G Trapani, G Wenz, G Zingone, GL Amidon, H Blode, H Hamada, H Matsuda, H Namazi, H Taira, H Yano, HA Archontaki, Helena M. Cabral Marques, HH Sigurdsson, HS Ganapathy, HS Woldum, Inês Sanches, IV Terekhova, J Cheng, J Králová, J Savolainen, J Szejtli, J Szejtli, J Xiong, JJ García-Rodriguez, João Arrais, JP Venter, JR Moyano, JS Smith, JW Wong, K Dua, K Minami, K Motoyama, K Nakanishi, K Okimoto, K Okimoto, K Okimoto, K Terao, K Udo, K Uekama, K Uekama, K Uekama, K-H Frӧmming, KP Chowdary, L Ribeiro, L Szente, L Trichard, M Agüeros, M Agüeros, M Charoenchaitrakool, M Cirri, M Echezarreta-López, M Fukuda, M Jug, M Jug, M Kamada, M Prabaharan, M Roux, M Sauceau, M Temtem, M Türk, M Usuda, M Yoshinari, M-J Zou, ME Zugasti, MT Esclusa-Díaz, MZI Khan, N Mourtzis, N Patel, N Zerrouk, N Zhang, N Özdemir, P Jansook, P Mura, P Mura, P Mura, P Mura, P Mura, Patrícia Pontes, Paulo José Salústio, PJ Salústio, R Cavalli, R Cavalli, R Challa, R Ficarra, R Garg, R Stancanelli, RL Carrier, S Petralito, S Péroche, S Sajeesh, S Sotthivirat, S Sotthivirat, S Szejtli, S Tommasini, S-Y Lee, Shishu, SM Badr-Eldin, T Endo, T Higashi, T Higashi, T Irie, T Loftsson, T Loftsson, T Loftsson, T Vasconcelos, T Yamanoi, V Burckbuchler, V Lemesle-Lamache, VM Rao, W Ling, W Sajomsang, X Lu, X Wen, X-M Liu, Y He, Y Ikeda, Y Ikeda, Y Liu, Y Liu, Y Lu, Y Tozuka, Y Zhou, Y-Z Du, Z Lu, Z Wang   +153 more
core   +1 more source

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source

Drug–drug interactions involving antidepressants: focus on desvenlafaxine

Neuropsychiatric Disease and Treatment, 2018
Yvette Low,1 Sajita Setia,2 Graca Lima3 1Department of Pharmacy, National University of Singapore, Singapore; 2Medical Affairs, Pfizer Pte. Ltd., Singapore; 3Global Medical Affairs, Asia-Pacific Region, Pfizer, Hong Kong Abstract: Psychiatric and ...
Low Y, Setia S, Lima G
doaj  

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Multimodal Nanobiophysical Profiling of Melanoma-Derived Small Extracellular Vesicles Reveals Glycan Signatures Associated with Tumor Progression

Nanotechnology, Science and Applications
Swamy Kasarla,1 Karolina Staniak,1,2 Magdalena Surman,3 Krystian Zajączkowski,1 Alicja Targońska,2 Grażyna Mosieniak,2 Konstancja Bobecka-Wesołowska,4 Josef Uskoba,5 Małgorzata Przybyło,3 ...
Kasarla S, Staniak K, Surman M, Zajączkowski K, Targońska A, Mosieniak G, Bobecka-Wesołowska K, Uskoba J, Przybyło M, Kobiela T   +9 more
doaj  

Molecular Dynamics Study of Charged Dendrimers in Salt-Free Solution: Effect of Counterions [PDF]

, 2005
Polyamidoamine (PAMAM) dendrimers, being protonated under physiological conditions, represent a promising class of nonviral, nano-sized vectors for drug and gene delivery. We performed extensive molecular dynamics simulations of a generic model dendrimer
Andrey A. Gurtovenko, Galperin D. E., Ilpo Vattulainen, Mikko Karttunen, Sergey V. Lyulin   +4 more
core   +3 more sources

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

Molecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix, Daniel Samaga, Katharina Gehr, Benedek Dankó, Mohamed Schumann, Guido Drexler, Ahmed Alnatsha, Georg Beyer, Ujjwal Mahajan, Martin Selmansberger, Julia Mayerle, Claus Belka, Horst Zitzelsberger, Kirsten Lauber   +13 more
wiley   +1 more source

Fluoroquinolone Efficacy against Tuberculosis Is Driven by Penetration into Lesions and Activity against Resident Bacterial Populations. [PDF]

, 2019
Fluoroquinolones represent the pillar of multidrug-resistant tuberculosis (MDR-TB) treatment, with moxifloxacin, levofloxacin, or gatifloxacin being prescribed to MDR-TB patients.
Alvarez-Cabrera, Nadine, Blanc, Landry, Dartois, Véronique, Dias-Freedman, Isabela, Dietzold, Jillian, Ho Liang, Hsin-Pin, Kaya, Firat, Kirschner, Denise, Linderman, Jennifer, Mina, Marizel, O'Brien, Paul, Pienaar, Elsje, Prideaux, Brendan, Salgame, Padmini, Sarathy, Jansy, Savic, Radojka M, Zimmerman, Matthew   +16 more
core   +2 more sources

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source